Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis
Authors:
Open Access
- 26 February 2019
- journal article
- review article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 58 (10) , 1839-1849
Abstract
Objective: The clinical impact of anti-drug antibodies (ADAbs) in paediatric patients with JIA remains unknown. This systematic review and meta-analysis aimed to summarize the prevalence of ADAbs in JIA studies; investigate the effect of ADAbs on treatment efficacy and adverse events; and explore the effect of immunosuppressive therapy on antibody formation. Methods: PubMed, Embase and the Cochrane Library were systematically searched to identify relevant clinical trials and observational studies that reported prevalence of ADAbs. Studies were systematically reviewed in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses and appropriate proportional and pairwise meta-analyses were performed. Results: A total of 5183 references were screened; 28 articles, involving 26 studies and 2354 JIA patients, met eligibility criteria. Prevalence of ADAbs ranged from 0% to 82% across nine biologic agents. Overall pooled prevalence of ADAbs was 16.9% (95% CI, 9.5, 25.9). Qualitative analysis of included studies indicated that antibodies to infliximab, adalimumab, anakinra and tocilizumab were associated with treatment failure and/or hypersensitivity reactions. Concomitant MTX uniformly reduced the risk of antibody formation during adalimumab treatment (risk ratio 0.33; 95% CI 0.21, 0.52). Conclusion: The association of ADAbs with treatment failure and hypersensitivity reactions indicates their clinical relevance in paediatric patients with JIA. Based on our findings, we recommend a preliminary course of action regarding immunogenicity of biologic agents in patients with JIA. Further strategies to predict, prevent, detect and manage immunogenicity could optimize treatment outcomes and personalize treatment with biologic therapies.Keywords
Funding Information
- Dutch Arthritis Foundation (RF 901)
This publication has 55 references indexed in Scilit:
- Long‐Term Safety and Efficacy of Rilonacept in Patients With Systemic Juvenile Idiopathic ArthritisArthritis & Rheumatism, 2013
- Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC RegisterAnnals of the Rheumatic Diseases, 2013
- Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritisNature Reviews Rheumatology, 2013
- Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic ArthritisNew England Journal of Medicine, 2012
- Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in JapanClinical Rheumatology, 2012
- The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a reviewArthritis Research & Therapy, 2010
- Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extensionAnnals of the Rheumatic Diseases, 2010
- The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cellsJournal of Experimental Medicine, 2009
- Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter studyClinical Rheumatology, 2008
- Formation, Distribution, and Elimination of Infliximab and Anti-Infliximab Immune Complexes in Cynomolgus MonkeysThe Journal of Pharmacology and Experimental Therapeutics, 2005